DOCSLIB.ORG

Inflammation and Cardiometabolic Risk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inflammation and Cardiometabolic Risk Official Publication of the National Lipid Association LipidSpin Inflammation and Cardiometabolic Risk Also in this issue: Clinical Trial Evidence for the Role of Reducing Inflammation for Cardiovascular Disease Prevention Identifying and Managing the Patient with High Inflammatory Burden Dietary Patterns and Systemic Inflammation: Examining the Connection This issue is sponsored by the Pacific Lipid Association. Volume 17 Issue 1 2019 visit www.lipid.org NATIONAL LIPID ASSOCIATION Turnberry Isle Miami 19999 W. Country Club Dr. SCIENTIFIC 9 Aventura, FL 33180 1 SESSIONS Group Rate: $229/night++ 0 Reservation Cut-Off Date: MIAMI 2 April 14, 2019 Pre-Conference Courses | May 15-16 Make your plans to join the NLA in 2019 for these premier events! lipid.org/conferences FEBRUARY 22-24 SEPTEMBER 13-15 2019 2019 PORTLAND MINNEAPOLIS Hilton Portland Downtown Renaissance Minneapolis Hotel, the Depot 921 SW Sixth Avenue, Portland, OR 97204 225 Third Avenue South, Minneapolis, MN 55401 Group Rate: $185/night++ Group Rate: $179/night++ Reservation Cut-Off Date: January 21, 2019 Reservation Cut-Off Date: August 14, 2019 Pre-Conference Courses | February 21-22, 2019 Pre-Conference Courses | September 12-13, 2019 In This Issue: 2019 (Volume 17, Issue 1) Editors DANIEL E. SOFFER, MD, FNLA* 2 From the NLA President 18 Practical Pearls Clinical Associate Professor of Medicine New Clinical Guidelines: Paving the Top 10 Ways to Reduce Inflammation University of Pennsylvania — Cezary Wójcik, MD, PhD, DSc, FNLA* Internal Medicine and Preventive Cardiology Road Ahead University of Pennsylvania Health System — Alan S. Brown, MD, FNLA* Philadelphia, PA — Daniel E. Soffer MD, FNLA* — Kaye-Eileen Willard MD, FNLA* KAYE-EILEEN WILLARD, MD, FNLA* 20 Case Study Medical Director, Lipid Clinic and Physician Advisor Identifying and Managing the Patient Ascension Wisconsin All Saints Racine, WI 4 From the PLA President with High Inflammatory Burden President’s Views — Michelle Taylor, CCRN, ANP Associate Editors — Nathan D. Wong, PhD, FNLA — Rob Greenfield, MD, FNLA* Lori A. Alexander, MSHS, RD, CCRC, CLS, FNLA; Christie M. Ballantyne, MD, FNLA*; Thomas A. Barringer, MD, FNLA*; Carolyn Burns, MD*; Ashley D. Davila, RN, MSN, Chapter Update CNS, CLS; Daniel A. Duprez, MD, PhD, FNLA; Debra A. 5 Editor’s Corner 23 Friedrich, DNP, ARNP, FNP, BC, CLS, FNLA; Raymond A. Sparking the Conversation on Focus on Member Engagement Gaskins, MD*; Douglas S. Jacoby, MD, FNLA*; Laney K. Inflammatory Disease Management — Nathan D. Wong, PhD, FNLA Jones, PharmD, MPH; Matthew D. Kostoff, PharmD, CLS; — Eric K. Gupta, PharmD, CLS, FNLA Spencer D. Kroll, MD, PhD, FNLA*; Merle Myerson, MD, — Daniel E. Soffer MD, FNLA* EdD, FNLA*; Hal Roseman, MD, FNLA*; Khalid H. Sheikh, — Michael D. Shapiro, DO, FNLA* MD, FNLA*; Mark Sherman, MD, FNLA; Leandro Slipczuk, — Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA MD, PhD; and Nathan D. Wong, PhD, FNLA 7 Clinical Feature — Yehuda Handelsman, MD, FNLA Executive Director Clinical Trial Evidence for the BRIAN HART, JD Role of Reducing Inflammation for 25 Specialty Corner National Lipid Association Cardiovascular Disease Prevention Dietary Patterns and Systemic LipidSpin is published five times a year by the — Bruce A. Warden, PharmD, BCPS-AQ Inflammation: Examining the National Lipid Association — Cezary Wójcik, MD, PhD, DSc, FNLA* 6816 Southpoint Parkway, Suite 1000 — Michael D. Shapiro, DO, FNLA* Connection Jacksonville, FL 32216 — Alyssa Lynott, RDN, LD Phone: 904-998-0854 | Fax: 904-998-0855 — Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA Copyright ©2019 by the NLA. All rights reserved. 11 Guest Editorial — Geeta Sikand, MA, RDN, CDE, CLS, FNLA Visit us on the web at lipid.org. High-sensitivity C-reactive Protein Versus Coronary Artery Calcium 29 Member Spotlight The National Lipid Association makes every effort to provide accurate information in the LipidSpin at the Scoring: Dissecting a Biological Wenjun Fan, MS time of publication; however, circumstances may alter Target from a Cardiovascular Risk certain details, such as dates or locations of events. Any changes will be denoted as soon as possible. The NLA Assessment Tool 30 Education, News and Notes invites members and guest authors to provide scientific — Anurag Mehta, MD and medical opinion, which do not necessarily reflect the — Amit Khera, MD, MSc policy of the Association. 31 Events Calendar Join the conversation on NLA social media! EBM Tools for Practice 14 Foundation Update Best Biomarkers for Inflammation 32 — Anne C. Goldberg, MD, FNLA facebook.com/nationallipid — Terrance J. Moran, MD, FNLA* twitter.com/nationallipid References Let’s Get Social facebook.com/nationallipid 16 Lipid Luminations 33 linkedin.com/company/national- Medications that Reduce twitter.com/nationallipidlipid-association Inflammation Also May Reduce 36 NLA Tear Sheet Cardiovascular Disease instagram.com/nationallipidinstagram.com/nationallipid — Eric K. Gupta, PharmD, CLS, FNLA linkedin.com/company/ lipid.org *indicatesnational-lipid-association ABCL Diplomate status Official Publication of the National Lipid Association 1 From the NLA President and Editors of LipidSpin: New Clinical Guidelines: Paving the Road Ahead ALAN S. BROWN, MD, FNLA DANIEL E. SOFFER, MD, FNLA President, National Lipid Association Editor, LipidSpin Director, Division of Cardiology Clinical Associate Professor of Medicine Advocate Lutheran General Hospital University of Pennsylvania Co-Director, Cardiology Service Line Internal Medicine and Preventive Cardiology Advocate Medical Group University of Pennsylvania Health System Clinical Associate Professor Philadelphia, PA Loyola Stritch School of Medicine Diplomate, American Board of Clinical Lipidology Park Ridge, IL Diplomate, American Board of Clinical Lipidology KAYE-EILEEN WILLARD, MD, FNLA Editor, LipidSpin Medical Director, Lipid Clinic and Physician Advisor Ascension Wisconsin All Saints Racine, WI Diplomate, American Board of Clinical Lipidology one-size-fits-all. The guidelines would on their merits (and shortcomings). have to be concise, clear, evidence-based, Based upon the response to retention flexible, universal, simple. They would hypothesis of atherosclerosis, observational, Discuss this article at have to provide the best advice for the genetic and clinical trial evidence, www.lipid.org/lipidspin greatest number of patients without therapeutic lipid and lipoprotein compromising advice to individuals. We management of ASCVD risk should think the 2018 Cholesterol Clinical Practice emphasize the following: Guidelines (CPGs)(1) accomplished that, “Knowing is not enough; we must apply. and we applaud the effort of the Writing • A healthy lifestyle is the foundation of Willing is not enough; we must do.” Committee. care for all individuals. This remark by Goethe introduces readers • One should reduce apolipoprotein B to the rationale for the Institute of Medicine As you know, the American Heart (apoB) containing lipoprotein levels of the National Academies Committee Association (AHA) and American College (primarily represented by the low- on Standards for Developing Trustworthy of Cardiology (ACC) enlisted the assistance density lipoprotein cholesterol (LDL- Clinical Practice Guidelines: Guidelines We of 10 other stakeholder organizations, C)) as much as possible by enhancing Can Trust 2011. including the National Lipid Association peripheral clearance of atherogenic (NLA), to ensure best practices, consensus lipoproteins, using statin drugs as the If you were asked to compose a set of and distribution of their recommendations foundation of pharmacotherapy. guidelines to advise clinicians on the best making up the 2018 Guidelines on the • The statin dose should be one used approach to cholesterol management, how Management of Blood Cholesterol, released in randomized placebo controlled would you write them? What if that same at AHA Scientific Sessions in November clinical trials (RPCTs), higher intensity set of guidelines was meant to inform 2018. Look for an upcoming LipidSpin issue preferred over moderate, and the goals health systems? Insurers? Other national dedicated exclusively to the Guidelines, for intensity of response should be health systems? They would have to be where NLA member authors will weigh in matched to ASCVD risk. 2 LipidSpin • Volume 17, Issue 1 • January 2019 • Since clinicians and patients do not 10-year risk of 7.5%-19.9% (intermediate Individual clinicians and patients can always know their pre-treatment lipid risk), risk-enhancing factors favor treat “beyond the Guidelines,” but should levels, there should also be thresholds initiation of statin therapy. recognize they do so with less evidence over which intensification of therapy 9. In adults 40-75 years without DM supporting care. In fact, there are many should be considered. and with LDL-C ≥70-189 mg/dL, at a examples where this makes sense, but • Since there is a high rate of attrition 10-year ASCVD risk of ≥7.5%-19.9%, it is not difficult to come up with a list with statin therapy, regular monitoring if a decision about statin therapy is of examples where this backfired (using to ensure medication tolerability, uncertain, consider measuring CAC. extended release niacin in our patients response to therapy and adherence to 10. Assess adherence and percentage achieving low LDL-C with moderate care is recommended. This begins with response to LDL-C–lowering intensity statin? Alpha-blockers as education and a shared discussion, and medications and lifestyle changes monotherapy for hypertension?
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • View Annual Report
    Annual Report Key Figures 2012 Group sales 45,499 millions of CHF +4% (CER) 1 Core operating profit 17,160 millions of CHF +11% (CER) Core earnings per share 13.62 CHF +10% (CER) Operating free cash flow 15,389 millions of CHF +10% (CER) R & D investment 8,475 millions of CHF +2% (CER) Dividend 2 7.35 CHF +8% (CER) Total Shareholder Return 2012 The value of CHF 100 3 invested 1/1/2012, for the period ending 31/12/2012 125 121 120 118 117 115 110 105 100 95 90 Dec Mar Jun Sep Dec 2011 2012 Roche GS, Price = 184.00 Roche B, Price = 186.90 Peer Set Index Patients on clinical trials 326,642 patients +10.4% Number of employees 4 82,089 employees +2.4% 1 CER: Constant exchange rates (average full-year 2011). 2 Proposed by the Board of Directors. 3 Prices translated at constant CHF exchange rates: USD=0.90; EUR=1.20; 100 JPY=1.10; GBP=1.40. 4 Full-time equivalents. Key Events 2012 Roche Group At the Roche Annual General Management changes: 3% Meeting in 2012, shareholders Daniel O’Day, former Head authorised a 3% dividend of Roche Diagnostics, was Daniel O’Day Daniel increase to CHF 6.80 per appointed the new Head of share and non-voting equity. Roche Pharma. Roland DiggelmannRoland It was the company’s 25 th Diggelmann has assumed dividend increase in as many the position of Head of years. Roche Diagnostics. Roche continued to streamline Our late-stage pipeline its research and develop- made considerable progress ment activities, taking the in 2012, with 11 out of 14 clini- decision to close its site in cal trials delivering positive Nutley, New Jersey, USA.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Study on Stabilization of Human Igg4 Antibodies
    九州大学学術情報リポジトリ Kyushu University Institutional Repository Study on stabilization of human IgG4 antibodies 浪崎, 博史 https://doi.org/10.15017/2534401 出版情報：九州大学, 2019, 博士（創薬科学）, 課程博士 バージョン： 権利関係： ヒト IgG4 抗体の安定化に関する研究 Study on stabilization of human IgG4 antibodies 2019 九州大学 大学院薬学府 臨床薬学部門 細胞生物薬学分野 浪崎 博史 1 略語表 CD; cluster of differentiation Ig; Immunoglobulin CDR; complementary determining region V; variable D; diversity J; joining RAG; recombination-activating gene RSS; recombination signal sequences TdT; terminal deoxynucleotidyl-transferase AID; activation induced cytidine deaminase BCR; B cell receptor TCR; T cell receptor Fab; fragment, antigen binding Fc; Fragment, Crystallizable VH; variable heavy CH; constant heavy VL; variable light CL; constant light CDC; complement-dependent cytotoxicity ADCC; antibody-dependent cellular cytotoxicity ADCP; antibody-dependent cellular phagocytosis NK; natural killer FcγR; Fc gamma receptor ITAM; immunoreceptor tyrosine-based activation motif 2 ITIM; immunoreceptor tyrosine-based inhibitory motif FcRn; neonatal Fc receptor PD-1; programmed cell death 1 PD-L1; programmed cell death –lignd1 VLA4; very late antigen-4 DNP; dinitrophenol ELISA; Enzyme-linked immunosorbent assay KD; dissociation constant SEC; size-exclusion chromatography DSF; differential scanning fluorimetry DSC; differential scanning calorimetry Tm; melting transition RU; resonance unit 3 目次 第一章 序論 p.5 １－１ 背景 p.5 １－１－１ 免疫グロブリンの種類および機能 p.5 １－１－２ 免疫グロブリンの多様性獲得 p.7 １－１－３ ヒト IgG の構造および機能 p.9 １－１－４ 抗体医薬の開発および承認状況 p.13 １－１－５ ヒト IgG4 の抗体医薬の研究開発状況 p.17 １－１－６ ヒト IgG サブクラスにおける安定性 p.21 １－２ 引用文献 p.25 第二章 ヒト IgG4 抗体の低 pH 誘導性凝集体形成における アミノ酸改変による抑制効果に関する研究 p.30 ２－１ 要旨 p.30 ２－２ 研究背景 p.32 ２－３ 材料および方法 p.35 ２－４ 結果 p.43 ２－５ 考察 p.78 ２－６ 引用文献 p.87 謝辞 p.94 4 第一章 序論 １－１ 背景 １－１－１ 免疫グロブリンの種類および機能 免疫グロブリン（Immunoglobulin；Ig）は哺乳細胞に存在する B 細胞から産生される 糖タンパク質であり、外来抗原を認識して結合する機能を有する。Ig は主に血液中 および組織体液中に存在し、細菌やウイルスなどの外来抗原に結合することにより、 白血球またはマクロファージによる食作用、ならびに免疫細胞の結合による免疫作 用により生体防御に関わっている。ヒトの免疫グロブリンは、IgG, IgA, IgM, IgD お よび IgE の 5 つのクラスが存在し (Fig.
    [Show full text]
  • Roche Group Development Pipeline
    Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group HY 2013 results Diagnostics Foreign exchange rate information 59 Changes to the development pipeline Q2 2013 update New to Phase I New to Phase II New to Phase III New to Registration 3 NMEs 3 NMEs 3 AIs 1 NME NDA submissions EU RG7410 in metabolic diseases RG7853 ALK inhibitor in NSCLC RG1273 Perjeta in HER2-positive and US RG7745 in infectious diseases RG7446 PD-L1 MAb in mNSCLC gastric cancer RG7159 obinutuzumab in CLL RG7842 in solid tumors RG7601 Bcl-2 inh in CLL RG435 Avastin in recurrent cervical 1 AI submission to FDA 3 AIs relapsed/refractory 17pdel cancer RG1273 Perjeta in neoadjuvant RG7446 PD-L1+Zelboraf in RG1569 Actemra in giant cell HER2-positive breast cancer metastatic melanoma arteritis RG7446 PD-L1 + Avastin in solid tumors RG7446 PD-L1 in solid tumors Removed from Removed from Phase I Removed from Phase II Removed from Phase III Registration 1 NME due to selection of 1 NME 2 NMEs 1 NME EU approval alternative molecule RG7160 imgatuzumab (GA201, RG1439 aleglitazar CV risk RG3616 Erivedge in advanced RG7112 MDM2 ant. in solid and EGFR MAb) in solid tumors reduction post ACS in type 2 basal cell carcinoma hematological tumors 2 AIs diabetes; complete programme 1 AI EU+US approval RG3638 onartuzumab in triple-neg terminated RG1569 RoActemra/Actemra in mBC 1st/2nd line SST arbaclofen in fragile X syndrome polyarticular
    [Show full text]
  • Antibody Based Therapy in Coronary Artery Disease and Heart Failure
    HEART RESEARCH ISSN 2377-164X http://dx.doi.org/10.17140/HROJ-4-140 Open Journal Review Antibody Based Therapy in Coronary *Corresponding author Artery Disease and Heart Failure Lorna R. Fiedler, PhD MRC Weatherall Institute of Molecular Medicine Oxford University * John Radcliffe Hosptial Lorna R. Fiedler, PhD Headley Way, Oxford OX3 9DS, UK E-mail: [email protected] MRC Weatherall Institute of Molecular Medicine, Oxford University, John Radcliffe Hosptial, Headley Way, Oxford OX3 9DS, UK Volume 4 : Issue 2 Article Ref. #: 1000HROJ4140 ABSTRACT Article History The function of the immune system is to protect the host against disease. Antibodies are a Received: June 4th, 2017 key part of the adaptive response, recognising specific antigens and invading pathogens and Accepted: July 6th, 2017 marking them for destruction or blocking their activities. A mechanistic and molecular un- Published: July 10th, 2017 derstanding of this process has allowed researchers to harness their natural function. They are now routinely used as a diagnostic tool in the clinic and in research to investigate pathological Citation signalling. More recently, antibodies have been utilised for another application – therapy. Anti- Fiedler LR. Antibody based therapy in body based therapy is one of the newest and fastest growing with nearly 70 approved drugs to coronary artery disease and heart fail- date and over 1000 in clinical trials. Investment from the pharmaceutical sector shows no signs ure. Heart Res Open J. 2017; 4(2): 39- of abating and this technology is now widely accepted for treating cancer, autoimmune and 45. doi: 10.17140/HROJ-4-140 infectious diseases.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]